$2.47
3.89%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US28106W1036
Symbol
EDIT

Editas Medicine, Inc. Stock price

$2.47
-0.09 3.52% 1M
+0.70 39.55% 6M
+1.20 94.49% YTD
-1.27 33.96% 1Y
-12.36 83.34% 3Y
-33.69 93.17% 5Y
-15.73 86.43% 10Y
-15.73 86.43% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.10 3.89%
ISIN
US28106W1036
Symbol
EDIT
Industry

Key metrics

Basic
Market capitalization
$222.1m
Enterprise Value
$100.3m
Net debt
positive
Cash
$178.5m
Shares outstanding
87.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.7 | 12.6
EV/Sales
2.6 | 5.7
EV/FCF
negative
P/B
11.6
Financial Health
Equity Ratio
39.3%
Return on Equity
-176.6%
ROCE
-111.2%
ROIC
-
Debt/Equity
3.0
Financials (TTM | estimate)
Revenue
$38.9m | $17.7m
EBITDA
$-154.1m | $-150.0m
EBIT
$-160.8m | $-161.0m
Net Income
$-236.9m | $-183.8m
Free Cash Flow
$-204.9m
Growth (TTM | estimate)
Revenue
-42.0% | -45.4%
EBITDA
25.6% | 35.6%
EBIT
24.5% | 32.6%
Net Income
-22.4% | 22.5%
Free Cash Flow
-19.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-396.1% | -849.7%
EBIT
-413.4%
Net
-608.9% | -1,040.8%
Free Cash Flow
-526.8%
More
EPS
$-2.8
FCF per Share
$-2.3
Short interest
9.1%
Employees
246
Rev per Employee
$130.0k
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Editas Medicine, Inc. forecast:

10x Buy
50%
8x Hold
40%
2x Sell
10%

Analyst Opinions

20 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
50%
Hold
40%
Sell
10%

Financial data from Editas Medicine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
39 39
42% 42%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
9% 9%
156%
- Research and Development Expense 139 139
35% 35%
357%
-154 -154
26% 26%
-396%
- Depreciation and Amortization 6.73 6.73
16% 16%
17%
EBIT (Operating Income) EBIT -161 -161
25% 25%
-413%
Net Profit -237 -237
22% 22%
-609%

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Neutral
Seeking Alpha
about 20 hours ago
Editas Medicine, Inc. - Special Call Company Participants Gilmore O'Neill - President, CEO & Director Linda Burkly - Executive VP & Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Samantha Semenkow - Citigroup Inc., Research Division Alec Stranahan - BofA Securities, Research Division Mehdi Goudarzi - Truist Securities, In...
Neutral
GlobeNewsWire
one day ago
EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401 today at 8:00 a.m. ET CAMBRIDGE, Mass.
Neutral
GlobeNewsWire
6 days ago
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 246
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today